TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a
global company specializing in disinfection and decontamination
utilizing its premier Binary Ionization Technology (BIT) platform
through its SteraMist brand of products, announced its financial
results for the second quarter of 2023.
TOMI Chief Executive Officer, Dr. Halden Shane, stated, “In the
second quarter we drove revenue growth which, given the high gross
margins in our business and continued management of our operating
expenses, resulted in a de minimis net loss and break even EPS.
“There has been a heavy focus placed on building sales
partnerships and expanding distribution channels and we are excited
with the progress made thus far in 2023. We added new distributors
in North America and Europe, and signed a contract with Vizient,
the largest group purchasing organization (GPO) in the healthcare
industry supplying around $100 billion in annual member purchasing
volume.
“We believe our second quarter results have us
back on track and establish momentum for us heading into the second
half of 2023. Given our current sales pipeline, the strength of our
high margin business model and high profitability on incremental
revenues, at this point in time we believe that we may attain
profitability in the fourth quarter. We remain focused on executing
our strategies to grow revenues, expand our sale network and
deliver improved results and values for our shareholders.”
Financial Results for the Three Months Ended June 30,
2023 compared to June 30, 2022
- Total net revenue was $2,775,000 compared to $1,458,000,
representing an increase of $1,317,000 or 90%. The
increase in revenue was largely due to strong growth in our product
and service revenue in the current year period as well as our
internal team’s ability to execute and deliver two iHP SteraMist
Custom Engineered Systems (CES) in the second quarter.
- Gross margin was 61% compared to 63%. The decrease in gross
profit was attributable to product mix in sales.
- Operating loss was ($89,000) compared to ($863,000). The
decline in our loss from operations was attributable to higher
sales and gross profit in the current year period.
- Net loss was ($89,000) or ($0.00) per basic and diluted share,
compared to ($862,000) or ($0.04) per basic share.
- Adjusted EBITDA was $2,000 compared to a loss of ($780,000) in
the same prior year period. A table reconciling EBITDA to the
appropriate GAAP financial measure is included with the Company’s
financial information below.
Financial Results for the Six Months Ended June 30, 2023
compared to June 30, 2022
- Total net revenue was $4,357,000 compared to $3,767,000,
representing an increase of $590,000 or 16%. The
increase in revenue was attributable to growth in our product and
service revenue.
- Gross margin was 61% compared to 62%. The decrease in gross
profit was attributable to product mix in sales.
- Operating loss was ($1,277,000) compared to
($1,523,000). The decline in our loss from operations
was attributable to higher sales and gross profit in the current
year period.
- Net loss was ($1,276,000) or ($0.06) per basic and diluted
share, compared to ($1,522,000) or ($0.08) per basic share.
- Adjusted EBITDA was a loss of ($939,000) compared to
($1,060,000). A table reconciling EBITDA to the appropriate GAAP
financial measure is included with the Company’s financial
information below.
Balance sheet highlights as of June 30,
2023
- Cash and cash equivalents were approximately $1.6 million.
- Working capital was $7.8 million.
- Shareholders’ equity was $10.4 million.
Recent Business Highlights:
- 100% growth quarter over quarter in SteraMist product revenues
for the three months ended June 30, 2023, compared to the same to
the same prior year period.
- 55% growth quarter over quarter in SteraMist iHP Service
revenue for the three months ended June 30, 2023, compared to the
same to the same prior year period.
- 116% growth in second quarter domestic revenue, when compared
to the same prior year period.
- 75% growth in 2023 second quarter sales compared to the first
quarter of 2023.
- Delivered an eleven (11) applicator CES system to Avid
Bioservices, Inc. (Avid) for implementation in Avid’s new
purpose-built viral vector development and manufacturing facility
in Costa Mesa, California.
- Announced Collaboration with Cellares to integrate our
SteraMist ionized Hydrogen Peroxide (iHP) technology into a
revolutionary new cell therapy manufacturing solution, the Cell
Shuttle, designed and produced by Cellares.
- Entered into a distributor agreement with Avantor, a Fortune
500 company and a leading supplier of mission-critical products and
services. We expect the distributor agreement to expand our sales
channels into the vital research, development, and production
activities in the biopharma, healthcare, education, government, and
advanced technologies and applied materials industries.
- Expanded our presence in Europe with the addition of
International Business Development (I.B.D.) as a distributor in
Italy.
- Entered into a contract with Vizient, Inc. increasing our
presence in the U.S. healthcare system. Vizient is the largest
group purchasing organization (GPO) in the healthcare industry
supplying around $100 billion in annual member purchasing volume.
Vizient serves approximately 97% of the nation’s Academic Medical
Centers, more than 50% of the nation’s acute care health system,
and serves more than 20% of the nation’s ambulatory market.
- Completion of a study conducted in accordance with the U.S.
Department of Defense (DoD) Biological Select Agents and Toxins
(BSAT) Biorisk Program Office (BBPO) which demonstrated SteraMist
iHP as an effective technology for decontamination of biological
toxoids.
- Attended and presented our SteraMist brand of products at the
following tradeshows, AORN Global Surgical Conference, Controlled
Environment Testing Association (CETA) International, Restoration
Industry Association (RIA) International, Lab Manager Leadership
Summit, FDIC International, Interphex, Food Safety Summit, and
Florida International Medical Expo (FIME).
- SteraMist technology was recognized as one of the Top 10
Infection Solution Providers of 2023 in the recent infection
control solutions special edition.
Conference Call Information
TOMI will hold a conference call to discuss Second Quarter 2023
results at 4:30 p.m. ET today, August 14, 2023.
To participate in the call by phone, dial (877) 545-0320
approximately five minutes prior to the scheduled start time and
reference the participant access code 559024 or request the "TOMI
Environmental Solutions second quarter earnings call."
International callers please dial (973) 528-0002. To access the
live webcast or view the press release, please visit the Investor
Relations section of the TOMI website or register at the following
link: https://www.webcaster4.com/Webcast/Page/2262/48885.
A replay of the teleconference will be available until Monday,
August 28, 2023, and may be accessed by dialing (877) 481-4010.
International callers may dial (919) 882-2331. Callers should use
replay access code: 48885. A replay of the webcast will be
available for at least 90 days on the company’s website, starting
approximately one hour after the completion of the call.
TOMI™ Environmental Solutions, Inc.: Innovating for
a safer world®TOMI™ Environmental Solutions, Inc.
(NASDAQ:TOMZ) is a global decontamination and infection prevention
company, providing environmental solutions for indoor surface
disinfection through the manufacturing, sales and licensing of its
premier Binary Ionization Technology® (BIT™) platform.
Invented under a defense grant in association with the Defense
Advanced Research Projects Agency (DARPA) of the U.S. Department of
Defense, BIT™ solution utilizes a low percentage Hydrogen
Peroxide as its only active ingredient to produce a fog of ionized
Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand
of products, iHP™ produces a germ-killing aerosol that works
like a visual non-caustic gas.TOMI products are designed to
service a broad spectrum of commercial structures, including, but
not limited to, hospitals and medical facilities, cruise ships,
office buildings, hotel and motel rooms, schools, restaurants, meat
and produce processing facilities, military barracks, police and
fire departments, and athletic facilities. TOMI products
and services have also been used in single-family homes and
multi-unit residences.
TOMI develops training programs and application protocols
for its clients and is a member in good standing with The American
Biological Safety Association, The American Association of Tissue
Banks, Association for Professionals in Infection Control and
Epidemiology, Society for Healthcare Epidemiology of America,
America Seed Trade Association, and The Restoration Industry
Association.
For additional information, please
visit http://www.tomimist.com/ or contact us
at info@tomimist.com.
Forward-Looking Statements
This press release contain forward-looking statements that are
based on current expectations, estimates, forecasts and projections
of future performance based on management’s judgment, beliefs,
current trends, and anticipated product performance. These
forward-looking statements include, without limitation, expected
sales pipeline; financial performance and operating results for
2023; upcoming launch of new products; expected growth in sales and
market demand; revenue opportunities of CES products and brand
recognition of our products. Forward-looking statements involve
risks and uncertainties that may cause actual results to differ
materially from those contained in the forward-looking statements.
These factors include, but are not limited to, the impact of
COVID-19 pandemic on our business and customers; our ability to
maintain and manage growth and generate sales, our reliance on a
single or a few products for a majority of revenues; the general
business and economic conditions; and other risks as described in
our SEC filings, including our Annual Report on Form 10-K for the
fiscal year ended December 31, 2022 filed by us with the SEC and
other periodic reports we filed with the SEC. The information
provided in this document is based upon the facts and circumstances
known at this time. Other unknown or unpredictable factors or
underlying assumptions subsequently proving to be incorrect could
cause actual results to differ materially from those in the
forward-looking statements. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, level of activity,
performance, or achievements. You should not place undue reliance
on these forward-looking statements. All information provided in
this press release is as of today’s date, unless otherwise stated,
and we undertake no duty to update such information, except as
required under applicable law.
Use of Non-GAAP Financial Measures
To supplement our unaudited consolidated financial statements
presented on a basis consistent with U.S. GAAP, we disclose certain
non-GAAP financial measures for our historical performance,
including EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin. We
define EBITDA as net income (loss), adjusted to exclude: interest,
taxes, depreciation and amortization (EBITDA) is a non-GAAP
financial measure and is intended to serve as a supplement to our
results provided in accordance with GAAP. We define Adjusted EBITDA
as net income (loss), adjusted to exclude: interest, taxes,
depreciation and amortization; stock-based compensation expense. We
define Adjusted EBITDA margin as Adjusted EBITDA divided by net
revenue. We believe that these historical non-GAAP financial
measures provide useful information to both management and
investors by excluding certain items and expenses that are not
indicative of our core operating results or do not reflect our
normal business operations. In addition, our management uses
non-GAAP measures to evaluate our performance internally and to
benchmark our performance externally against competitors. Our use
of non-GAAP financial measures has certain limitations in that such
non-GAAP financial measures may not be directly comparable to those
reported by other companies. Although we believe that the use of
non-GAAP financial measures enhances its investors’ understanding
of its business and performance, our use of non-GAAP financial
measures should not be considered an alternative to GAAP basis
financial measures and should be read in conjunction with the
relevant GAAP financial measures. Other companies may use the same
or similarly named measures, but exclude different items, which may
not provide investors with a comparable view of our performance in
relation to other companies. Because of these limitations, the
non-GAAP financial measure used in this release should not be
considered in isolation or as a substitute for performance measures
calculated in accordance with GAAP. We seek to compensate for the
limitation of our non-GAAP presentation by providing a detailed
reconciliation of the non-GAAP financial measures to the most
directly comparable U.S. GAAP as set forth below. Investors are
encouraged to review the related U.S. GAAP financial measures and
the reconciliation of these non-GAAP financial measures to their
most directly comparable U.S. GAAP financial measures.
TOMI ENVIRONMENTAL SOLUTIONS, INC. |
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
|
|
|
ASSETS |
|
|
|
Current
Assets: |
|
|
|
June 30, 2023 (Unaudited) |
December 31, 2022 |
Cash and Cash Equivalents |
$ |
1,574,088 |
|
|
$ |
3,866,733 |
|
Accounts Receivable - net |
|
3,379,150 |
|
|
|
2,772,340 |
|
Other Receivables |
|
164,150 |
|
|
|
164,150 |
|
Inventories |
|
4,412,786 |
|
|
|
4,495,999 |
|
Vendor Deposits |
|
203,459 |
|
|
|
447,052 |
|
Prepaid Expenses |
|
291,224 |
|
|
|
388,359 |
|
Total Current Assets |
|
10,024,857 |
|
|
|
12,134,633 |
|
|
|
|
|
Property and Equipment –
net |
|
1,238,241 |
|
|
|
1,335,331 |
|
|
|
|
|
Other Assets: |
|
|
|
Intangible Assets – net |
|
1,018,189 |
|
|
|
1,025,736 |
|
Operating Lease - Right of Use
Asset |
|
499,369 |
|
|
|
528,996 |
|
Capitalized Software
Development Costs - net |
|
- |
|
|
|
- |
|
Other Assets |
|
565,540 |
|
|
|
475,103 |
|
Total Other Assets |
|
2,083,098 |
|
|
|
2,029,835 |
|
Total Assets |
$ |
13,346,196 |
|
|
$ |
15,499,799 |
|
|
|
|
|
LIABILITIES AND
SHAREHOLDERS’ EQUITY |
|
Current Liabilities: |
|
|
|
Accounts Payable |
$ |
1,360,438 |
|
|
$ |
1,761,750 |
|
Accrued Expenses and Other
Current Liabilities |
|
646,130 |
|
|
|
728,703 |
|
Deferred Revenue |
|
146,381 |
|
|
|
699,732 |
|
Current Portion of Long-Term
Operating Lease |
|
109,318 |
|
|
|
100,282 |
|
Total Current Liabilities |
|
2,262,267 |
|
|
|
3,290,467 |
|
|
|
|
|
Long-Term Liabilities: |
|
|
|
Long-Term Operating Lease, Net
of Current Portion |
|
701,974 |
|
|
|
761,132 |
|
Total Long-Term Liabilities |
|
701,974 |
|
|
|
761,132 |
|
Total Liabilities |
|
2,964,241 |
|
|
|
4,051,599 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ Equity: |
|
|
|
Cumulative Convertible Series A Preferred Stock; |
|
|
|
par value $0.01 per share, 1,000,000 shares authorized; 63,750
shares issued |
|
|
and outstanding at June 30, 2023 and December 31, 2022 |
|
638 |
|
|
|
638 |
|
Cumulative Convertible Series B Preferred Stock; $1,000 stated
value; |
|
|
7.5% Cumulative dividend; 4,000 shares authorized; none issued |
|
|
and outstanding at June 30, 2023 and December 31, 2022 |
|
- |
|
|
|
- |
|
Common stock; par value $0.01 per share, 250,000,000 shares
authorized; |
|
|
19,823,955 and 19,763,855 shares issued and outstanding |
|
|
|
at June 30, 2023
and December 31, 2022, respectively. |
|
198,240 |
|
|
|
197,640 |
|
Additional Paid-In Capital |
|
57,882,792 |
|
|
|
57,673,559 |
|
Accumulated Deficit |
|
(47,699,715 |
) |
|
|
(46,423,637 |
) |
Total Shareholders’ Equity |
|
10,381,955 |
|
|
|
11,448,200 |
|
Total Liabilities and
Shareholders’ Equity |
$ |
13,346,196 |
|
|
$ |
15,499,799 |
|
|
|
|
|
|
TOMI ENVIRONMENTAL SOLUTIONS, INC. |
|
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
|
|
|
|
|
|
|
|
|
|
|
|
|
For The Three Months Ended |
|
For The Six Months Ended |
|
|
|
June 30, |
|
June 30, |
|
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
Sales, net |
|
$ |
2,774,699 |
|
|
$ |
1,458,395 |
|
|
$ |
4,356,871 |
|
|
$ |
3,766,978 |
|
Cost of Sales |
|
|
1,074,420 |
|
|
|
537,103 |
|
|
|
1,715,355 |
|
|
|
1,424,991 |
|
Gross Profit |
|
|
1,700,279 |
|
|
|
921,292 |
|
|
|
2,641,516 |
|
|
|
2,341,987 |
|
|
|
|
|
|
|
|
|
|
|
Operating
Expenses: |
|
|
|
|
|
|
|
|
Professional Fees |
|
|
111,660 |
|
|
|
94,796 |
|
|
|
248,845 |
|
|
|
285,326 |
|
Depreciation and Amortization |
|
|
90,560 |
|
|
|
82,751 |
|
|
|
179,336 |
|
|
|
165,043 |
|
Selling Expenses |
|
|
501,045 |
|
|
|
565,945 |
|
|
|
877,698 |
|
|
|
906,734 |
|
Research and Development |
|
|
73,728 |
|
|
|
99,350 |
|
|
|
144,248 |
|
|
|
136,426 |
|
Consulting Fees |
|
|
68,912 |
|
|
|
39,535 |
|
|
|
144,367 |
|
|
|
102,745 |
|
General and Administrative |
|
|
943,314 |
|
|
|
901,632 |
|
|
|
2,324,108 |
|
|
|
2,268,256 |
|
Total Operating Expenses |
|
|
1,789,219 |
|
|
|
1,784,009 |
|
|
|
3,918,602 |
|
|
|
3,864,530 |
|
Income (loss) from Operations |
|
|
(88,940 |
) |
|
|
(862,717 |
) |
|
|
(1,277,086 |
) |
|
|
(1,522,543 |
) |
|
|
|
|
|
|
|
|
|
|
Other Income
(Expense): |
|
|
|
|
|
|
|
|
Interest Income |
|
|
349 |
|
|
|
335 |
|
|
|
1,008 |
|
|
|
678 |
|
Total Other Income
(Expense) |
|
|
349 |
|
|
|
335 |
|
|
|
1,008 |
|
|
|
678 |
|
|
|
|
|
|
|
|
|
|
|
Income (loss)
before income taxes |
|
|
(88,591 |
) |
|
|
(862,382 |
) |
|
|
(1,276,078 |
) |
|
|
(1,521,865 |
) |
Provision for
Income Taxes |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Net Income
(loss) |
|
$ |
(88,591 |
) |
|
$ |
(862,382 |
) |
|
$ |
(1,276,078 |
) |
|
$ |
(1,521,865 |
) |
|
|
|
|
|
|
|
|
|
|
Net income (loss)
Per Common Share |
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.00 |
) |
|
$ |
(0.04 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.08 |
) |
Diluted |
|
$ |
(0.00 |
) |
|
$ |
(0.04 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.08 |
) |
|
|
|
|
|
|
|
|
|
|
Basic Weighted
Average Common Shares Outstanding |
|
|
19,823,955 |
|
|
|
19,717,919 |
|
|
|
19,815,336 |
|
|
|
19,703,012 |
|
Diluted Weighted
Average Common Shares Outstanding |
|
|
19,823,955 |
|
|
|
19,717,919 |
|
|
|
19,815,336 |
|
|
|
19,703,012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following is a reconciliation of net income (loss) to EBITDA
and Adjusted EBITDA:
|
|
|
For The Three Months Ended |
|
For The Six Months Ended |
|
|
|
June 30, |
|
June 30, |
|
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
Net income
(loss) |
|
$ |
(88,591 |
) |
|
$ |
(862,382 |
) |
|
$ |
(1,276,078 |
) |
|
$ |
(1,521,865 |
) |
|
|
|
|
|
|
|
|
|
|
|
Interest Income |
|
(349 |
) |
|
|
(335 |
) |
|
|
(1,008 |
) |
|
|
(678 |
) |
|
Depreciation and Amortization |
|
90,560 |
|
|
|
82,751 |
|
|
|
179,336 |
|
|
|
165,043 |
|
|
Other |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
EBITDA (Loss) |
|
$ |
1,620 |
|
|
$ |
(779,966 |
) |
|
$ |
(1,097,750 |
) |
|
$ |
(1,357,500 |
) |
|
|
|
|
|
|
|
|
|
|
|
Equity Compensation
Expense |
|
|
- |
|
|
|
- |
|
|
|
158,833 |
|
|
|
297,766 |
|
|
Other |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Adjusted EBITDA (Loss) |
|
$ |
1,620 |
|
|
$ |
(779,966 |
) |
|
$ |
(938,917 |
) |
|
$ |
(1,059,734 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
$ |
2,774,699 |
|
|
$ |
1,458,395 |
|
|
$ |
4,356,871 |
|
|
$ |
3,766,978 |
|
|
Adjusted EBITDA Margin |
|
|
0 |
% |
|
|
-53 |
% |
|
|
-22 |
% |
|
|
-28 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INVESTOR RELATIONS CONTACT:John Nesbett/Roz ChristianIMS
Investor Relationstomi@imsinvestorrelations.com
TOMI Environmental Solut... (NASDAQ:TOMZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
TOMI Environmental Solut... (NASDAQ:TOMZ)
Historical Stock Chart
From Apr 2023 to Apr 2024